Oncology

Latest News

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.

The data presented at ASCO reflect patients seen during 2 community health fairs designed to reach underserved populations in Georgia. | Image credit: NIKCOA - stock.adobe.com
Teledermatology Shows Promise to Reduce Disparities in Skin Cancer Screening

June 18th 2025

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
February 19th 2020

Lessons From the Front: Designing and Implementing Clinical Pathways by and for Clinicians

David M. Jackman, MD Joanna Hamilton, MA, MS Emily Foster, MPH Craig A. Bunnell, MD, MPH, MBA Louis Culot, MA Carole Tremonti, RN, MBA Joseph O. Jacobson, MD, MSc
As cancer care becomes more complex and more expensive, decision-support algorithms offer a mechanism to define best practice, reduce unwarranted variation, and control costs across growing networks.
This Week in Managed Care: February 7, 2020
February 8th 2020

This Week in Managed Care: February 7, 2020

This week, top managed care stories included survey results on oncology practices’ willingness to take on risk; a warning of flu among children in detention centers; study findings establishing a link between circadian rhythm and type 2 diabetes.
Dr Joshua Ofman: Improving Survival, Reducing Costs in Oncology Vital to Value-Based Care Transition
February 6th 2020

Dr Joshua Ofman: Improving Survival, Reducing Costs in Oncology Vital to Value-Based Care Transition

From a value-based medicine perspective, we think there's no greater value in the healthcare system than improving survival for cancer patients and reducing the costs of treating late stage cancer; we believe the GRAIL test could be the test case for how to make this transition, said Joshua Ofman, MD, MSHS, chief of Corporate Strategy and External Affairs at GRAIL Inc.
Site Logo
February 5th 2020

A Population-Based Assessment of Proton Beam Therapy Utilization in California

Arti Parikh-Patel, PhD, MPH Cyllene R. Morris, DVM, PhD Frances B. Maguire, PhD, MPH Megan E. Daly, MD Kenneth W. Kizer, MD, MPH
This population-based analysis of patients with cancer in California found significant differences in proton beam therapy use by health insurance type, race/ethnicity, and socioeconomic status.
Site Logo
January 28th 2020

American Oncology Network, LLC, Names Todd Schonherz President and Chief Operating Officer

Schonherz will be responsible for day-to-day operations.
CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers
January 28th 2020

CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers

Allison Inserro Mary Caffrey
CMS said it is expanding coverage of next generation sequencing (NGS) for use as a diagnostic for patients with germline breast and ovarian cancer, paving the way for Medicare beneficiaries to receive more personalized medicine. However, an advocate said the wording of CMS' decision could actually limit testing access for some women with breast or ovarian cancer.
Site Logo
January 21st 2020

Bundled Payments: Looking Back, Looking Ahead

Alyssa Dahl, MPH
Jennifer Atkins Explains How Blue Cross Blue Shield Evaluates Emerging Innovations in Cancer Care
January 17th 2020

Jennifer Atkins Explains How Blue Cross Blue Shield Evaluates Emerging Innovations in Cancer Care

Blue Cross Blue Shield utilizes data to drive insights into what works and what doesn't work in cancer care, as well as, delineating trends through our collaboration with provider specialties and organizations across the US, said Jennifer Atkins, MBA, vice president of Network Solutions at Blue Cross Blue Shield.
When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds
January 4th 2020

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds

Mary Caffrey
Testicular cancer is the most common cancer to be diagnosed in men as younger men—those younger than age 40—and it can be particularly aggressive. Advances in therapy have improved survival rates, but if young men have chemotherapy after surgery, they may live with side effects for decades.
What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer
January 2nd 2020

What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer

AJMC Staff
Five issues in healthcare were spotlighted as key developments to watch; FDA to ban all e-cig vape flavors except for menthol and tobacco; Google AI system shown to improve detection of breast cancer through mammograms.
An Immune-Suppressing Target for Glioblastoma?
December 27th 2019

An Immune-Suppressing Target for Glioblastoma?

Mary Caffrey
A team at The University of Texas MD Anderson Cancer Center in Houston led by original pioneers in immuno-oncology have published a paper in Nature Medicine that discusses an immune-suppressing enzyme that was strongly present in glioblastoma but not in 5 other tumor types the team studied.
Site Logo
December 19th 2019

Improving Survival in Lung Cancer: Commitment of The Lung Ambition Alliance

Giorgio Scagliotti, MD, PhD
For more than 45 years, the International Association for the Study of Lung Cancer has been working tirelessly toward a world without lung and other thoracic cancers. To add strength to our efforts we recently joined with other leading organizations in the lung cancer space to create a powerful force for change: The Lung Ambition Alliance
Future of BCC and CSCC Therapy
December 19th 2019

Future of BCC and CSCC Therapy

Second-Line Systemic Treatment of BCC
December 19th 2019

Second-Line Systemic Treatment of BCC

Systemic Therapy in BCC
December 19th 2019

Systemic Therapy in BCC

Electing for Surgery in the Management of BCC
December 19th 2019

Electing for Surgery in the Management of BCC

Overview of Basal Cell Carcinoma
December 19th 2019

Overview of Basal Cell Carcinoma

Toxicity Profile and Pseudoprogression
December 19th 2019

Toxicity Profile and Pseudoprogression

PD-1 and Other Systemic Treatment Options for CSCC
December 19th 2019

PD-1 and Other Systemic Treatment Options for CSCC

Using Immunotherapy in CSCC
December 19th 2019

Using Immunotherapy in CSCC

Systemic Treatment of CSCC
December 19th 2019

Systemic Treatment of CSCC

Standard of Care for CSCC
December 19th 2019

Standard of Care for CSCC

Overview of Cutaneous Squamous Cell Carcinoma
December 19th 2019

Overview of Cutaneous Squamous Cell Carcinoma

Site Logo
December 18th 2019

Radiation Oncologist Discusses Concerns With Incoming CMS Payment Model

Allison Inserro
As CMS prepares to move forward with new models of value-based cancer care, a radiation oncologist, speaking at the Institute for Value-Based Medicine®, discussed her findings regarding whether accountable care models had an effect on cancer care spending.
Site Logo
December 18th 2019

Hope and Some Skepticism Whether Oncology Payment Models Will Work

Allison Inserro
Coverage from the Institute for Value-Based Medicine® session held in Nashville, Tennessee.
Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines
December 18th 2019

Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines

Maggie L. Shaw
In cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), there is a greater risk of symptomatic heart failure in the first year following initiation of anthracycline treatment.
Government-Insured Patients With Breast Cancer Face a Higher Risk of Death
December 17th 2019

Government-Insured Patients With Breast Cancer Face a Higher Risk of Death

Gianna Melillo
Patients with breast cancer who have government insurance face a higher risk of death, according to a retrospective study presented at the 2019 San Antonio Breast Cancer Symposium on December 13.
Site Logo
December 17th 2019

From the Editor-in-Chief: Lead, Follow, or Get Out of the Way

Joseph Alvarnas, MD
Dr Alvarnas is editor-in-chief of Evidence-Based Oncology.™ He is vice president of Government Affairs, senior medical director for Employer Strategy, and associate clinical professor, Hematology & Hematologic Cell Transplantation, City of Hope, Duarte, Califonia.
Site Logo
December 16th 2019

Provider Perspective: Stephen M. Schleicher, MD, MBA, Addresses Accountability Versus Control in Oncology Care First

Mary Caffrey
An article Schleicher co-wrote in JAMA Oncology, which appeared the day before the announcement of Oncology Care First, offered insights into the need for changes to the original OCM.
Site Logo
December 16th 2019

Provider Perspective: Kashyap Patel, MD, Sees Collaboration Going Into Oncology Care First

Mary Caffrey
Kashyap Patel, MD, the chief executive officer of Carolina Blood and Cancer Care Associates—a leading OCM practice—and associate editor of Evidence-Based Oncology™ (EBO), said he’s optimistic about Oncology Care First.
<1
...
202122232425262728
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo